Phathom Pharmaceuticals (PHAT) Non-Current Assets (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Non-Current Assets data on file, last reported at $28.5 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $28.5 million, down 2.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.6 million (up 62.78% YoY), and the FY2025 annual result was $30.2 million, up 65.95% from the prior year.
• Non-Current Assets declined to $28.5 million in Q1 2026 per PHAT's latest filing, from $30.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $32.5 million in Q3 2025 and troughed at $3.3 million in Q1 2022.
• A 5-year average of $15.8 million and a median of $14.6 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets dropped 6.9% in 2022, then soared 288.41% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $4.3 million in 2022, then surged by 281.81% to $16.4 million in 2023, then rose by 10.81% to $18.2 million in 2024, then soared by 65.95% to $30.2 million in 2025, then slipped by 5.39% to $28.5 million in 2026.
• Business Quant data shows PHAT's Non-Current Assets at $28.5 million in Q1 2026, $30.2 million in Q4 2025, and $32.5 million in Q3 2025.